Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
This research aims to provide continued access to study treatments for participants with pulmonary hypertension who have completed previous clinical studies but have no other treatment alternatives. The study evaluates the long-term safety of these treatments, including macitentan, selexipag, and a fixed dose combination of macitentan and tadalafil. It is a phase 3, open-label study sponsored by Actelion. Participants who have completed parent studies and still benefit from their assigned treatment will continue receiving their study drug orally during this follow-up study. Adults typically take macitentan once daily, selexipag twice daily at their maintenance dose, or the macitentantadalafil combination once daily. Children aged 2 years and older receive doses adjusted by body weight. Study visits occur every 6 months for adults and every 3 months for pediatric participants, continuing until treatment becomes commercially available, an equivalent therapy is accessible, the participant withdraws, or the study ends early. During the study, participants undergo regular assessments to monitor safety and treatment effects, including collection of adverse event data, treatment discontinuations, serious adverse events, and deaths over up to 84 months. Visits include on-site evaluations of efficacy and safety. This long-term monitoring helps researchers understand the safety profile of these treatments when used beyond the initial clinical trials.
Actively Recruiting
Researchers are evaluating the tolerability, safety, and effectiveness of a gene therapy called GNR-097 for boys aged 4 to 9 years with Duchenne muscular dystrophy DMD. The study includes two phases Phase I involves two dose groups receiving increasing amounts of the gene therapy, and Phase II is a randomized, single-blind, placebo-controlled study where some participants receive placebo initially with the option to receive gene therapy in the second year. Participants will receive a single intravenous infusion of GNR-097 on Day 1 during Phase I. In Phase II, participants randomized to placebo will receive a matching placebo infusion on Day 1, then have the option to receive the gene therapy infusion at the start of the second year. The study aims to determine the best dose in Phase I and assess safety and efficacy in Phase II with placebo control. Throughout the study, participants will be monitored for adverse events and safety from baseline through Week 104. Researchers will evaluate treatment-emergent adverse events, serious adverse events, and adverse events of special interest. Participants will undergo assessments of functional activity and immune response, and their health will be tracked during screening, treatment, and follow-up periods. The total study duration spans up to approximately four years from the start date in 2025 to completion in 2029.
Actively Recruiting
Researchers are conducting a multinational phase III study to optimize therapy for children and adolescents with acute lymphoblastic leukemia ALL in complete remission who require allogeneic hematopoietic stem cell transplantation HSCT with a myeloablative conditioning regimen. The study aims to compare chemotherapy-based conditioning regimens with total body irradiation TBI combined with etoposide, focusing on treatment outcomes and side effects. This research addresses the need for safer conditioning options due to the significant long-term toxicities associated with TBI in growing patients. Participants receive different conditioning regimens before HSCT based on age, donor type, and country-specific protocols. The main options include TBI with etoposide for patients older than 4 years, and chemotherapy combinations such as fludarabine, thiotepa, treosulfan, busulfan, and cyclophosphamide for younger patients or those ineligible for TBI. Various donor types, including matched sibling donors, matched unrelated donors, and mismatched donors, are included, with additional treatments like ATG or T-cell depletion depending on donor matching. Throughout the study, participants undergo regular evaluations including survival monitoring and adverse event tracking for up to 10 years. Assessments focus on overall survival, event-free survival, relapse, and treatment-related toxicity. Data collection includes long-term follow-up to investigate factors affecting outcomes such as immune recovery, graft-versus-host disease, and pharmacogenomics. The total study duration can extend to several years to thoroughly assess late effects and survival rates.
Actively Recruiting
Researchers are evaluating the efficacy, tolerability, and safety of a single intraperitoneal dose of the investigational drug Prospidelong in patients with disseminated gastric cancer. This open-label, prospective, randomized clinical study plans to include 120 patients aged 18 to 75 years, divided evenly into two groups one receiving Prospidelong and the other serving as a comparison group. The study aims to assess survival and other health outcomes over an average of two years. Participants receive one dose of Prospidelong 4000 mg, equivalent to 2000 mg of prospidium chloride administered directly into the abdominal cavity after diagnostic surgery. The control group undergoes diagnostic surgery followed by systemic chemotherapy according to approved clinical protocols. After treatment, all patients continue with standard care and chemotherapy as specified by national guidelines. During the study, patients are monitored daily throughout their hospital stay and during follow-up visits. Assessments include physical exams, blood tests, urine analyses, ultrasound or CT scans, and evaluation of performance status using the ECOG scale at multiple time points up to two years post-surgery. Researchers track safety, treatment tolerability, and survival as primary outcomes, with imaging and laboratory tests as secondary measures.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of anti-BCMA CAR-T cell immunotherapy for adults with relapsed or refractory multiple myeloma. This study includes both Phase I and Phase II to explore safety concerns such as cytokine release syndrome and infections, as well as the treatments overall response and survival rates. The trial is sponsored by the Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology and focuses on patients resistant to prior therapies. Participants receive locally manufactured, second-generation autologous humanized anti-BCMA CAR-T cells. The treatment process involves leukapheresis to collect T cells, followed by a lymphodepleting chemotherapy regimen with fludarabine and cyclophosphamide before receiving a single CAR-T cell infusion. The dose ranges from 50 million to 250 million cells. The study evaluates pharmacokinetics and monitors for adverse events during both phases. During the trial, participants undergo monitoring for safety within one month post-infusion and evaluation of treatment response up to twelve months. Additional assessments include progression-free survival, overall survival, and duration of response over three years. Researchers track CAR-T cell expansion and peak levels. The total study duration extends until 2030, with regular clinical visits and laboratory evaluations throughout the follow-up period.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, how the body processes, and immune response to BCD-236 combined with chemotherapy in women with relapsed or metastatic triple negative breast cancer TNBC who have received previous treatments. This is a Phase 2 study that compares BCD-236 plus chemotherapy versus chemotherapy alone in patients whose cancer has returned or progressed after earlier therapies. Participants will be randomly assigned to one of two groups one receiving BCD-236 by intravenous infusion plus chemotherapy chosen by the investigator, and the other receiving chemotherapy alone. Treatment continues until the cancer worsens, side effects become intolerable, or the study ends. During the study, participants will undergo regular assessments including tumor measurements and health evaluations to monitor response and side effects. The main outcome measured is the overall response rate at 24 weeks, with secondary outcomes including progression-free survival, overall survival, disease control rate, time to response, and duration of response assessed at various times up to 102 weeks. Participants will be monitored closely throughout their treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a combination drug containing clotrimazole and lactulose compared to clotrimazole alone in adult women diagnosed with candidal vulvovaginitis. The study aims to determine if the combination drug provides better clinical and microbiological recovery by Day 25 of treatment. This trial uses an adaptive design to assess how lactulose affects fungal infections in the vagina. Participants are randomly assigned to one of three groups one receiving vaginal suppositories with clotrimazole 100 mg and lactulose 300 mg, another receiving vaginal tablets with clotrimazole 100 mg alone, and a third group receiving vaginal suppositories with lactulose 300 mg alone. The study evaluates outcomes at several visits Day 8, Day 15, and Day 25, focusing on symptom improvement, microbiological response, and changes in vaginal bacteria. During the study, participants will undergo clinical assessments and laboratory tests to measure symptom severity and vaginal bacterial content, including molecular analysis of Lactobacillus levels. Patient satisfaction with the therapy will also be recorded. Safety and treatment responses will be monitored throughout the 25-day period, with the main result being the proportion of patients who achieve full clinical and microbiological recovery by Day 25.
Actively Recruiting
This research aims to evaluate the real-life effectiveness, safety, and usage patterns of Octapharmas factor VIII FVIII concentratesNuwiq, Octanate, and Wilatein patients with severe haemophilia A who have either never been treated or have had minimal treatment. The study focuses on previously untreated patients, often young children, and minimally treated patients, gathering more data on treatment outcomes and inhibitor development to better understand optimal treatment approaches in routine clinical practice. Participants receive one of the three FVIII concentrates Nuwiq recombinant FVIII, Octanate plasma-derived FVIII, or Wilate plasma-derived FVIII combined with von Willebrand factor. The study observes how these products are used, including dosing and frequency, without altering prescribed treatments. This non-interventional study collects data during routine care to assess product utilization, safety, and effectiveness, including responses to surgical prophylaxis. During the study, researchers monitor participants for breakthrough bleeding rates and any adverse drug reactions over 100 exposure days to assess treatment effectiveness and safety. They also collect information on FVIII dosing and physicians evaluations of surgical prophylaxis effectiveness. The study involves patients of all ages and follows them through their usual clinical visits, with data gathered via observation rather than treatment changes. The study is designed to provide valuable real-world evidence on these FVIII concentrates in severe haemophilia A patients.
Actively Recruiting
Researchers are studying chronic myeloid leukemia CML, a rare blood cancer, in children and adolescents under 18 years old. This international observational study aims to better understand the characteristics, treatment approaches, and prognostic factors of pediatric CML. It also seeks to evaluate the long-term effects of treatments, especially tyrosine kinase inhibitors, on growth and development in this young population. The study collects both retrospective and prospective data from medical records and databases, without administering new treatments or interventions. Data gathered include demographic details, diagnosis information, treatment histories, and follow-up outcomes. National coordinating centers in participating countries gather anonymized patient data and send it to a central data center in France for analysis. Participants data are collected and updated twice yearly, with ongoing monitoring to describe patient characteristics and treatment policies. Researchers analyze survival, response to treatment, side effects, and long-term outcomes. The study is expected to continue for about five years, with results shared regularly with participating centers and published anonymously.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Myval Transcatheter Heart Valve THV Series compared to Contemporary Valves, including the Sapien THV Series and Evolut THV Series, in patients with severe symptomatic native aortic valve stenosis. This multinational, prospective, randomized trial involves 768 participants and aims to assess whether the Myval device performs at least as well as the other commercially available valves in improving heart valve function. Participants will be randomly assigned to receive either the Myval THV Series or one of the Contemporary Valves via a transfemoral approach. The Myval devices come in various sizes ranging from 20 mm to 29 mm, with additional registries for extra-large sizes. Separate study groups include a non-randomized nested registry for extra-large Myval devices and a lead-in set to ensure procedural adherence by investigators before enrolling subjects. During the study, participants will undergo assessments including clinical evaluations and imaging to monitor valve function and safety over time. Outcomes measured include a combined safety and effectiveness endpoint at 30 days, as well as longer-term monitoring for mortality, stroke, kidney injury, valve performance, and quality of life up to 10 years. The study involves follow-ups at multiple timepoints to comprehensively evaluate the devices performance and patient health.
1-10 of 18
1